alexa VIP and PACAP as Regulators of Immunity: New Perspectives from A Receptor Point of View | OMICS International| Abstract

Journal of Clinical & Experimental Neuroimmunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Clin Exp Neuroimmunol 1:104,

VIP and PACAP as Regulators of Immunity: New Perspectives from A Receptor Point of View

Catalina Abad and Yossan-Var Tan*
Inserm U905, University of Rouen, Institute for Research and Innovation in Biomedicine (IRIB), , Rouen, Normandy, France
*Corresponding Author : Yossan-Var Tan, Inserm U905, University of Rouen, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, Normandy, France, Tel: (33)-02-35-14-8233, Email: [email protected]

Received Date: Feb 11, 2016 / Accepted Date: Mar 12, 2016 / Published Date: Mar 15, 2016

Abstract

Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) are two neuropeptides acting through three common G-protein coupled receptors (VPAC1, VPAC2 and PAC1). Among their pleiotropic actions within the organism, VIP and PACAP are known to exhibit immunomodulatory properties in both the innate and adaptive immune axes. The fact that they inhibit inflammation in murine models of disease has brought these peptides into the spotlight within the field of therapeutic discovery for autoimmune/inflammatory diseases. Pharmacological tools and transgenic mice have been useful in order to investigate the involvement of each of their three receptors in these actions. This review focuses on the relevance of the VPAC2 receptor on VIP and PACAP modulation of immune responses, and discusses its potential as a target for the treatment of Th1-driven inflammatory disorders.

Keywords: Vasoactive intestinal peptide (VIP); Inflammatory diseases; Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)

Citation: Abad C, Var Tan Y (2016) VIP and PACAP as Regulators of Immunity: New Perspectives from A Receptor Point of View. J Clin Exp Neuroimmunol 1:104.

Copyright: © 2016 Abad C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences

26th World Congress on Neurology and Neurodisorders

Singapore, Singapore
Article Usage
  • Total views: 10095
  • [From(publication date): 3-2016 - Aug 11, 2020]
  • Breakdown by view type
  • HTML page views: 9900
  • PDF downloads: 195

Review summary

  1. Bernard Peterson
    Posted on Sep 26 2016 at 11:25 am
    The review is very well written. Brief elucidation about some future studies regarding the role of VCAP2 in human clinical trials and any new studies done in humans is highly recommended.
Top